Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Hemmingsen, Bianca ^a   Lund, Søren S ^b   Gluud, Christian ^a   Vaag, Allan ^a   Almdal, Thomas P ^c   Wetterslev, Jørn ^a  

^a Rigshospitalet   (Denmark)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; ADULT; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; META ANALYSIS; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84957415695     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008143.pub4     Document Type: Review

References (272)

1. Action to Control Cardiovascular Risk in Diabetes Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Protocol. http://www.accordtrial.org/web/public/documents/Protocol%20All%20Chapters.pdf?CFID=411958&CFTOKEN=23567741 Assessed January 05, 2009.
2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, GoffDC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine 2008;358(24):2545-59.
3. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, GoffDC Jr, Bigger JT, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. The New England Journal of Medicine 2011;364(9):818-28. [PUBMED: 21366473]
4. Anderson RT, Narayan KM, Feeney P, GoffD Jr, Ali MK, Simmons DL, et al. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care 2011;34(4):807-12. [PUBMED: 21346183]
5. Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. The American Journal of Cardiology 2007;99(12A):80i-9i.
6. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909. [PUBMED: 20061358]
7. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. The American Journal of Cardiology 2007;99(12A):21i-33i. [PUBMED: 17599422]
8. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. The New England Journal of Medicine 2010;363(3):233-44. [PUBMED: 20587587]
9. Cushman WC, Evans GW, Byington RP, GoffDC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. The New England Journal of Medicine 2010;362(17):1575-85. [PUBMED: 20228401]
10. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. The New England Journal of Medicine 2010;362(17):1563-74. [PUBMED: 20228404]
11. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376(9739):419-30. [PUBMED: 20594588]
12. The ADDITION Study. Intensive Treatment in People With Screen Detected Diabetes in Primary Care. (ADDITION). http://www.clinicaltrials.gov 10/10-2005. [NCT00237549]
13. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378(9786):156-67. [PUBMED: 21705063]
14. Simmons RK, Sharp SJ, Sandbaek A, Borch-Johnsen K, Davies MJ, Khunti K, et al. Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial. Diabetic Medicine 2012;29(11):e409-16. [PUBMED: 22823477]
15. Webb DR, Khunti K, Gray LJ, Srinivasan BT, Farooqi A, Wareham N, et al. ADDITION-Leicester study group. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected type 2 diabetes mellitus: a cluster randomized controlled trial. Diabetic Medicine 2012;29(4):531-40. [PUBMED: 21913966]
16. van den Donk M, Gorter KJ, Rutten GE. No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients. The ADDITION-Netherlands study. Quality of Life Research 2010;19(4):509-13. [PUBMED: 20155327]
17. Webb DR, Khunti K, Gray LJ, Srinivasan BT, Farooqi A, Wareham N, et al. ADDITION-Leicester study group. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected type 2 diabetes mellitus: a cluster randomized controlled trial. Diabet Med 2012;29(4):531-40. [PUBMED: 21913966]
18. van den Donk M, Gorter KJ, Rutten GE. No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients. The ADDITION-Netherlands study. Quality of Life Research 2010;19(4):509-13. [PUBMED: 20155327]
19. ADVANCE Collaborative Group. ADVANCE Study Design and Methodology. http://www.advance-trial.com Assessed January 05, 2009.
20. Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009;52(10):2027-36. [PUBMED: 19633827]
21. Clarke PM, Glasziou P, Patel, Chalmers J, Woodward M, Harrap SB, Salomon JA, on behalf of the ADVANCE Collaborative Group. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Medicine 2010;7(2):e1000236. [DOI: 10.1371; PUBMED: 1000236]
22. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008;358(24):2560-72.
23. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. The New England Journal of Medicine 2010;363(15):1410-8. [PUBMED: 20925543]
24. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009;32(11):2068-74.
25. Araki A. Japan Elderly Diabetes Intervention Study. UMIN-CTR Clinical Trial 2007. [UMIN000000890]
26. Araki A, Iimuro S, Sakurai T, Umegaki H, Iijima K, Nakano H, et al. Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial--study design, baseline characteristics and effects of intervention. Geriatrics & Gerontology International 2012;12 Suppl 1:7-17. [PUBMED: 22435936]
27. Araki S, Nishio Y, Araki A, Umegaki H, Sakurai T, Iimuro S, et al. Factors associated with progression of diabetic nephropathy in Japanese elderly patients with type 2 diabetes: sub-analysis of the Japanese Elderly Diabetes Intervention Trial. Geriatrics & Gerontology International 2012;12 Suppl 1:127-33. [PUBMED: 22435948]
28. Bagg W. Cardiac and endothelial function is unaffected by short-term intensive glycaemic control in patients with type-2 diabetes mellitus [abstract]. Internal Medicine Journal 2001;31:A1.
29. Bagg W, Ferri C, Desideri G, Gamble G, Ockelford P, Braatvedt GD. The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2001;86(11):5491-7.
30. Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2001;3(6):410-6.
31. Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N, Braatvedt GD, et al. Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Internal Medicine Journal 2001;31(6):322-8.
32. Becker A, van der Does FEE, van Hinsbergh VWM, Heine RJ, Bouter LM, Stehouwer CDA. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, von Willebrand factor and (pro)insulin. Netherlands Journal of Medicine 2003;61(4):129-36.
33. van der Does FE, de Neeling JN, Snoek FJ, Grootenhuis PA, Kostense PJ, Bouter LM, et al. Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1 year. Diabetes Care 1998;21(12):2085-93. [PUBMED: 9839098]
34. Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes, Obesity & Metabolism 2009;11(6):623-31. [PUBMED: 19515182]
35. Novo Nordisk. Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (TITRATE™). http://www.clinicaltrials.gov/ct/show/NCT00634842.
36. Cao SG, Ren JA, Shen B, Chen D, Zhou YB, Li JS. Intensive versus conventional insulin therapy in type 2 diabetes patients undergoing D2 gastrectomy for gastric cancer: a randomized controlled trial. World Journal of Surgery 2011;35(1):85-92. [PUBMED: 20878324]
37. Cao SG, Zhou YB, Zhang CK, Chen D, Yu YY, Lu LF. [Effect of intensive insulin therapy on the clinical results of postoperative patients with gastric cancer]. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery] 2008;46(12):918-20. [PUBMED: 19035150]
38. Wang QG, Lu LF, Zhou YB, Cao SG, Wang DS, Lv L. [Effects of intensive insulin therapy on insulin resistance and serum proteins after radical gastrectomy]. Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery 2008;11(5):444-7. [PUBMED: 18803046]
39. Cooray G, Nilsson E, Wahlin A, Laukka EJ, Brismar K, Brismar T. Effects of intensified metabolic control on CNS function in type 2 diabetes. Psychoneuroendocrinology 2011;36(1):77-86. [PUBMED: 20656408]
40. DIGAMI Trial Group. Diabetes mellitus and insulin glucose infusion in acute myocardial infarction - DIGAMI 2. Provided by the investigators 1996.
41. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal 2005;26(7):650-61.
42. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 2011;54(6):1308-17. [PUBMED: 21359582]
43. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. European Heart Journal 2008;29(2):166-76.
44. Intravenous Insulin in Patients With Diabetes After Percutaneous Coronary Intervention (PCI). www.clinicaltrials.gov. [NCT00967642]
45. Fantin Sde S, Wainstein MV, Polanczyk CA, Ledur P, Lazzari CM, Klein C, et al. Inflammatory and oxidative stress markers after intravenous insulin in percutaneous coronary intervention with stent in type 2 diabetes mellitus: a randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism 2011;96(2):478-85. [PUBMED: 21084403]
46. Guo LX, Pan Q, Wang XX, Li H, Zhang LN, Chi JM, et al. Effect of short term intensive multitherapy on carotid intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus. Chinese Medical Journal 2008;121(8):687-90.
47. Hage C, Norhammar A, Grip L, Malmberg K, Sarkar N, Svane B, et al. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. Diabetes and Vascular Disease Research 2009;6(2):71-9.
48. Yngen M, Norhammar A, Hjemdahl P, Wallen NH, Yngen M, Norhammar A, et al. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diabetes and Vascular Disease Research 2006;3(1):52-6.
49. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Annals of Pharmacotherapy 1996;30(3):238-43.
50. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-Insulin-dependent diabetes-mellitus - A randomized prospective 6-year study. Diabetes Research and Clinical Practice 1995;28(2):103-17.
51. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23 Suppl 2(0149-5992 (Print)):B21-9.
52. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Research and Clinical Practice 2000;48(3):201-10.
53. Lu WH, Shi BY, Zhang XT, Wei DG, Liu WD, Duan PZ. Significance of intensive glycemic control on early diabetic nephropathy patients with microalbuminuria. Academic Journal of Xi'an Jiaotong University 2010;22(2):135-8.
54. Melidonis A, Stefanidis A, Tournis S, Manoussakis S, Handanis S, Zairis M, et al. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clinical Cardiology 2000;23(3):160-4.
55. Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. The STent Restenosis And Metabolism (STREAM) study. www.clinicaltrials.gov. [NCT00412126]
56. Natarajan MK, Strauss BH, Rokoss M, Buller CE, Mancini GB, Xie C, et al. Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. Cardiovascular Revascularization Medicine 2012;13(2):95-100. [PUBMED: 22296781]
57. Lapina YV, Filatov DN, Mareev VY, Yu O, Bolotina MG, Shestakova MV, et al. Effect of strict glycemic control on clinical state and course of the disease in patients with chronic heart failure and Type II diabetes mellitus. Results of the REMBO "Rational Effective Multicomponent Therapy in the Struggle Against DiaBetes Mellitus in Patients With COngestve Heart Failure" Study. Kardiologiya 2008;48(9):17-27.
58. Service FJ, Daube JR, O'Brien PC, Zimmerman BR, Swanson CJ, Brennan MD, et al. Effect of blood glucose control on peripheral nerve function in diabetic patients. Mayo Clinic Proceedings 1983;58(5):283-9.
59. Stefanidis A, Melidonis A, Tournis S, Zairis M, Handanis S, Beldekos D, et al. Effect of intravenous insulin administration on left ventricular performance during non-ST-elevation acute coronary events in patients with diabetes mellitus. The American Journal of Cardiology 2003;91(10):1237-40. [PUBMED: 12745109]
60. Stefanidis A, Melidonis A, Tournis S, Zairis M, Handanis S, Olympios C, et al. Intensive insulin treatment reduces transient ischaemic episodes during acute coronary events in diabetic patients. Acta Cardiologica 2002;57(5):357-64. [PUBMED: 12405574]
61. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. The New England Journal of Medicine 2008;358(6):580-91.
62. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31(8):1510-5.
63. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal of Medicine 2003;348(5):383-93.
64. Gaede P, Vedel P, Parving HH, Pedersen O, Gaede P, Vedel P, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353(9153):617-22.
65. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978;240(1):37-42.
66. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, Methods and Baseline Results. Diabetes 1970; Vol. 19:747-72.
67. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality Results. Diabetes 1970; Vol. 19:789-830.
68. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 1982;31 Suppl 5:1-81. [PUBMED: 6757026]
69. Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001;44(3):298-304. [PUBMED: 11317659]
70. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48(5):868-77.
71. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine 2008;359(15):1577-89. [PUBMED: 18784090]
72. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006;49(8):1761-9. [PUBMED: 16736131]
73. U.K. Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22(7):1125-36. [PUBMED: 10388978]
74. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-65.
75. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
76. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia 1991;34(12):877-90.
77. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine 1997;157(2):181-8.
78. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995;18(8):1113-23.
79. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care 1992;15(11):1560-71.
80. Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998;21(4):574-9.
81. Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, et al. Evaluations of retinopathy in the VA cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Diabetes Care 1996;19(12):1375-81.
82. Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000;23(10):1478-85.
83. Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C, et al. Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes and its Complications 2005;19(4):207-11.
84. Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2 Veterans Affairs Diabetes Trial. Journal of Diabetes and its Complications 2003;17(6):314-22.
85. Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity & Metabolism 2009;11(2):150-6. [PUBMED: 18671796]
86. Agrawal L, Azad N, Emanuele NV, Bahn GD, Kaufman DG, Moritz TE, et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes care 2011;34(9):2090-4. [PUBMED: 21775749]
87. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine 2009;360(2):129-39.
88. Yang JM, Guo XH, Yu X. Long-term intensive glycemic and lipid control ameliorates the carotid intima medial thickness in type 2 diabetes mellitus. Beijing da xue xue bao. Yi xue ban (Journal of Peking University. Health Sciences) 2007;39(6):649-52. [PUBMED: 18087561]
89. Zhang Q, Zhang N, Hu HL, He Y, Chen MW, Wang XY, et al. Effect of intensive blood glucose control on quality of life in elderly patients with type 2 diabetes in Anhui Province. Chinese Medical Journal 2011;124(11):1616-22. [PUBMED: 21740765]
90. Abdelmalak B, Maheshwari A, Kovaci B, Mascha EJ, Cywinski JB, Kurz A, et al. Validation of the DeLiT Trial intravenous insulin infusion algorithm for intraoperative glucose control in noncardiac surgery: a randomized controlled trial. Canadian Journal of Anaesthesia (Journal Canadien d'Anesthesie) 2011;58(7):606-16. [PUBMED: 21598057]
91. Abdelmalak B, Maheshwari A, Mascha E, Srivastava S, Marks T, Tang WW, et al. Design and organization of the Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT) Trial: a factorial trial evaluating the effects of corticosteroids, glucose control, and depth-of-anesthesia on perioperative inflammation and morbidity from major non-cardiac surgery. BMC Anesthesiology 2010;10:11. [PUBMED: 20591163]
92. Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2010;33(1):177-83. [PUBMED: 19808911]
93. Asma A, Azmi MN, Mazita A, Marina MB, Salina H, Norlaila M. A single blinded randomized controlled study of the effect of conventional oral hypoglycemic agents versus intensive short-term insulin therapy on pure tone audiometry in type II diabetes mellitus. Indian Journal of Otolaryngology and Head and Neck Surgery 2011;63(2):114-8. [PUBMED: 22468245]
94. Barbosa J, Connett J, Fryd D, Sutherland D, Rao V, Anderson R, et al. The Minnesota diabetes complications clinical trial. The first three years. Acta Diabetologica Latina 1983;20(2):165-71. [PUBMED: 6308933]
95. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009;120(25):2529-40. [PUBMED: 19920001]
96. Barnett AH, Barnett Anthony H. Treatment intensification in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2008;10 Suppl 1:iii.
97. Blaha J, Kopecky P, Matias M, Hovorka R, Kunstyr J, Kotulak T, et al. Comparison of three protocols for tight glycemic control in cardiac surgery patients. Diabetes Care 2009;32(5):757-61. [PUBMED: 19196894]
98. Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, et al. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. Journal of Nephrology 2001;14(6):461-71.
99. Brown JR, Furnary AP, Mackenzie TA, Duquette D, Helm RE, Paliotta M, et al. Does tight glucose control prevent myocardial injury and inflammation?. The Journal of Extra-Corporeal Technology 2011;43(3):144-52. [PUBMED: 22164453]
100. Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care 2009;32(6):977-82. [PUBMED: 19460913]
101. Chen SY, Chang YH, Hsu HC, Lee YJ, Hung YJ, Hsieh CH. One-year efficacy and safety of the telehealth system in poorly controlled type 2 diabetic patients receiving insulin therapy. Telemedicine Journal and e-Health 2011;17(9):683-7. [PUBMED: 21882998]
102. Chen SM, Creedy D, Lin HS, Wollin J. Effects of motivational interviewing intervention on self-management, psychological and glycemic outcomes in type 2 diabetes: a randomized controlled trial. International Journal of Nursing Studies 2012;49(6):637-44. [PUBMED: 22209215]
103. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006;29(4):765-70. [PUBMED: 16567812]
104. Clark R S, English M, McNeill G P, Newton R W. Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. British Medical Journal (Clinical research ed.) 1985;291(6491):303-5.
105. Clauson P, Karlander S, Steen L, Efendic S. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. Diabetic Medicine 1996;13(5):471-7. [PUBMED: 8737030]
106. Cleveringa FGW, Minkman MH, Gorter KJ, Van den Donk M, Rutten GEHM. Diabetes Care Protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care. Diabetic Medicine 2010;27(4):442-50.
107. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. Journal of the American College of Cardiology 2004;43(1):8-14. [PUBMED: 14715174]
108. Crasto W, Jarvis J, Khunti K, Skinner TC, Gray LJ, Brela J, et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research and Clinical Practice 2011;93(3):328-36. [PUBMED: 21640424]
109. Desimone ME, Blank GE, Virji M, Donihi A, DiNardo M, Simak DM, et al. Effect of an educational inpatient diabetes management pogram on medical resident knowledge and measures of glycemic control: a randomized controlled trial. Endocrine Practice 2012;18(2):238-49. [PUBMED: 22440993]
110. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. European Heart Journal 1996;17(9):1337-44. [PUBMED: 8880018]
111. Du JL, Liu JF, Men LL, Yao JJ, Sun LP, Sun GH, et al. Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus. Chinese Medical Journal 2009;122(21):2560-6. [PUBMED: 19951570]
112. Eastman RC, Eastman RC. Is intensive glycemic control worth the expense?. Cleveland Clinic Journal of Medicine 1997;64(8):410-3.
113. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. European Journal of Clinical Investigation 2004;34(3):205-9. [PUBMED: 15025679]
114. Evans RJ, Lane J, Holman RR, Turner RC. Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes. Diabetes Care 1982;5(4):433-7. [PUBMED: 6818012]
115. Farcasiu E, Ivanyi T, Mozejko-Pastewka B, Birkus Z, Csog J, Kowalska I, et al. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study. Clinical Therapeutics 2011;33(11):1682-93. [PUBMED: 22036246]
116. Fenske WK, Pournaras DJ, Aasheim ET, Miras AD, Scopinaro N, Scholtz S, et al. Can a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass?. Obesity Surgery 2012;22(1):90-6. [PUBMED: 22052198]
117. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. The Annals of Thoracic Surgery 1999;67(2):352-60; discussion 360-2. [PUBMED: 10197653]
118. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32(3):381-6. [PUBMED: 19246588]
119. Hu Y, Li L, Xu Y, Yu T, Tong G, Huang H, et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission. Diabetes Care 2011;34(8):1848-53. [PUBMED: 21680726]
120. Johansen OE, Gullestad L, Blaasaas KG, Orvik E, Birkeland KI. Effects of structured hospital-based care compared with standard care for type 2 diabetes - The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial. Diabetic Medicine 2007;24(9):1019-27. [PUBMED: 17509068]
121. Joss N. Intensive medical management in type 2 diabetes and nephropathy: renal consequences [abstract no: SU-P0860]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):646A.
122. Kanaoka T, Tamura K, Moriya T, Tanaka K, Konno Y, Kondoh S, et al. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 2011;33(4):255-63. [PUBMED: 21699452]
123. Kawamori R, Kamada T. Determination of the glycemic threshold for the regression or prevention of diabetic microangiopathies, and the insulin injection regimen to establish strict glycemic control in NIDDM. Japanese Journal of Medicine 1991;30(6):618-21. [PUBMED: 1798230]
124. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004;109(12):1497-502. [PUBMED: 15006999]
125. Leibowitz G, Raizman E, Brezis M, Glaser B, Raz I, Shapira O. Effects of moderate intensity glycemic control after cardiac surgery. Annals of Thoracic Surgery 2010;90(6):1825-32.
126. MacMahon Tone J, Agha A, Sherlock M, Finucane F, Tormey W, Thompson CJ. An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. Irish Journal of Medical Science 2009;178(2):179-86. [PUBMED: 19367427]
127. Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP, et al. Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics 2011;36(5):602-13. [PUBMED: 21143256]
128. Menard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. Canadian Medical Association Journal 2005;173(12):1457-66. [PUBMED: 16293781]
129. Naqvi AH, Malik A, Rasool F, Khan Z. Early morbidity and mortality in patients with tight glycaemic control versus standard control. The Professional Medical Journal 2011;18(3):396-401.
130. Nerenberg KA, Goyal A, Xavier D, Sigamani A, Ng J, Mehta SR, et al. Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial. Diabetes Care 2012;35(1):19-24. [PUBMED: 22074724]
131. Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ (Clinical research ed.) 2001;323(7319):970-5. [PUBMED: 11679387]
132. Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. Diabetic Medicine 2010;27(2):175-80. [PUBMED: 20546261]
133. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine 2012;367(4):319-28. [PUBMED: 22686416]
134. Piatt GA, Anderson RM, Brooks MM, Songer T, Siminerio LM, Korytkowski MM, et al. 3-year follow-up of clinical and behavioral improvements following a multifaceted diabetes care intervention: results of a randomized controlled trial. The Diabetes Educator 2010;36(2):301-9. [PUBMED: 20200284]
135. Pimazoni-Netto A, Rodbard D, Zanella MT. on behalf of the Diabetes Education and Control Group. Rapid improvement of glycemic control in type 2 diabetes using weekly intensive multifactorial interventions: structured glucose monitoring, patient education, and adjustment of therapy - a randomized controlled trial. Diabetes Technology & Therapeutics 2011;13(10):997-1004. [PUBMED: PMC3182678]
136. PlotnikoffRC, Pickering MA, Glenn N, Doze SL, Reinbold-Matthews ML, McLeod LJ, et al. The effects of a supplemental, theory-based physical activity counseling intervention for adults with type 2 diabetes. Journal of Physical Activity & Health 2011;8(7):944-54. [PUBMED: 21885885]
137. Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. A structured self-monitoring of blood glucose approach in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: results from the STeP study. Diabetes Technology & Therapeutics 2011;13(8):797-802. [PUBMED: 21568751]
138. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366(9493):1279-89. [PUBMED: 16214598]
139. Rauch, et al. 4th Annual Meeting of the Diabetes and Cardiovascular Disease EASD Study Group. Munich, Germany, 2011.
140. Opsteen C, Qi Y, Zinman B, Retnakaran R. Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. Journal of Evaluation in Clinical Practice 2012;18(2):256-61. [PUBMED: 20846320]
141. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes, Obesity & Metabolism 2010;12(1):65-71. [PUBMED: 19740080]
142. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27(5):1028-32. [PUBMED: 15111515]
143. Schaan B, Moraes MA, Rodrigues J, Cremonesi M. Implementation of a diabetes management protocol compared to conventional management in a heart hospital's non-intensive care unit: Randomised clinical trial. 3 Meeting Abstracts. 2011.
144. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. The New England Journal of Medicine 2012;366(17):1567-76. [PUBMED: 22449319]
145. Shi Q, Ostwald SK, Wang S. Improving glycaemic control self-efficacy and glycaemic control behaviour in Chinese patients with type 2 diabetes mellitus: randomised controlled trial. Journal of Clinical Nursing 2010;19(3-4):398-404. [PUBMED: 20500279]
146. Tian J, Wang J, Li Y, Villarreal D, Carhart R, Dong Y, et al. Endothelial function in patients with newly diagnosed type 2 diabetes receiving early intensive insulin therapy. American Journal of Hypertension 2012;25(12):1242-8. [PUBMED: 22895449]
147. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999;22(6):960-4. [PUBMED: 10372249]
148. van Bruggen R, Gorter K, Stolk R, Klungel O, Rutten G. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Family Practice 2009;26(6):428-36. [PUBMED: 19729401]
149. Vivas D, Garcia-Rubira JC, Bernardo E, Angiolillo DJ, Martin P, Calle-Pascual A, et al. Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo"). Heart (British Cardiac Society) 2011;97(10):803-9. [PUBMED: 21378389]
150. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371(9626):1753-60. [PUBMED: 18502299]
151. Wexler DJ, Beauharnais CC, Regan S, Nathan DM, Cagliero E, Larkin ME. Impact of inpatient diabetes management, education, and improved discharge transition on glycemic control 12 months after discharge. Diabetes Research and Clinical Practice 2012;98(2):249-56. [PUBMED: 23036785]
152. Zhao XH, Xu ZR, Lu XY, Zhang Q, Yang YM. [Changes of blood pressure, blood glucose and blood lipids levels after intensive treatment in incipient diabetes II patients]. Zhejiang da xue xue bao. Yi xue ban (Journal of Zhejiang University. Medical sciences) 2010;39(2):198-201. [PUBMED: 20387250]
153. Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study (ADVANCE-ON). Ongoing study January 2010.
154. The Benefits of Intensive Glycemic Control in Elderly Patients With Type 2 Diabetes. Ongoing study February 2009.
155. DARE: Diabetes in cArdiac REhabilitation. Ongoing study July 2005.
156. GLUCOSURG1 (Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery). Ongoing study December 2010.
157. HFDM (Optimized Glycemic Control in Heart Failure Patients With DM2: "Effect on Left Ventricular Function and Skeletal Muscle"). Ongoing study March 2010.
158. LIMBISCH (Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty). Ongoing study December 2008.
159. REMIT Pilot Trial (Remission Evaluation of Metabolic Interventions in Type 2 Diabetes). Ongoing study September 2010.
160. Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT). Ongoing study 2012.
161. The VA Diabetes Trial Follow-up Study (VADT-FS). Ongoing study February 2008.
162. The Effect of Intensive Multifactorial Therapy on Endothelial Function in Newly Diagnosed Type 2 Diabetes. Ongoing study April 2010.
163. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 2009;15(6):540-59. [PUBMED: 19858063]
164. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, GoffDC Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. The New England Journal of Medicine 2011;364(9):818-28. [PUBMED: 21366473]
165. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20(7):1183-97. [PUBMED: 9203460]
166. American Diabetes Association. The expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 Suppl 1:1-114.
167. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26 Suppl 1:5-20. [PUBMED: 12502614]
168. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31 Suppl 1:12-54. [PUBMED: 18165335]
169. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36 Suppl 1:S11-66. [PUBMED: 23264422]
170. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36(4):1033-46. [PUBMED: 23468086]
171. American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28(5):1245-9. [PUBMED: 15855602]
172. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62-9. [DOI: 10.2337/dc10-S062.]
173. Agency for Healthcare Research and Quality. Applicability of the Evidence Regarding Intensive Glycemic Control and Self-Monitored Blood Glucose to Medicare Patients with Type 2 Diabetes. Technology Assessment 10/09/2007:1-83.
174. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13, 000 men and women with 20 years of follow-up. Archives of Internal Medicine 2004;164(13):1422-6. [PUBMED: 15249351]
175. Bliss M. Resurrections in Toronto: the emergence of insulin. Hormone Research 2005;64 Suppl 2:98-102. [PUBMED: 16286782]
176. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ (Clinical research edition) 2010;340:b4909. [PUBMED: 20061358]
177. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ (Clinical research ed.) 2011;343:d4169. [PUBMED: 21791495]
178. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9. [PUBMED: 18411040]
179. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
180. Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012;Issue 6:Art. No.: CD007543. DOI: 10.1002/14651858.CD007543.pub2. [PUBMED: 22696371]
181. Calles-Escandon J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33(4):721-7. [PUBMED: 20103550]
182. Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37, 229 patient meta-analysis. American Heart Journal 2011;162(5):938-48.e2. [PUBMED: 22093212]
183. Chan AW, TetzlaffJM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Clinical research ed.) 2013;346:e7586. [PUBMED: 23303884]
184. Ciani O, Buyse M, Garside R, Pavey T, Stein K, Sterne JA, et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ (Clinical research ed.) 2013;346:f457. [PUBMED: 23360719]
185. Englewood NJ. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-analysis Version 2, Biostat, Englewood NJ. Englewood NJ, 2005.
186. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Archives of Internal Medicine 2012;172(10):761-9. [PUBMED: 22636820]
187. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
188. Cohen D. Insiders criticise FDA's decision not to withdraw rosiglitazone. BMJ 2010; Vol. 341:c5333. [PUBMED: 20880925]
189. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361(9374):2005-16. [PUBMED: 12814710]
190. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57(12):3169-76. [PUBMED: 19033403]
191. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52(9):1766-77. [PUBMED: 19572116]
192. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375(9713):481-9. [PUBMED: 20110121]
193. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine 2005;353(25):2643-53. [PUBMED: 16371630]
194. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22(5):756-61. [PUBMED: 10332677]
195. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
196. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
197. EMA. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim [-]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1 2010.
198. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58(6):579-88. [PUBMED: 15878471]
199. Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology 2006;163(6):493-501. [PUBMED: 16443796]
200. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46(4):734-42. [PUBMED: 17316871]
201. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1999;159(22):2661-7. [PUBMED: 10597756]
202. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52(9):1732-44. [PUBMED: 19565214]
203. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews (Online) 2011;15(6):CD008143 doi: 10.1002/14651858.CD008143.pub2. [PUBMED: 21678374]
204. Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews (Online) 2013;4:CD009008 doi: 10.1002/14651858.CD009008.pub2. [PUBMED: 23633364]
205. Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. Statistics in Medicine 2011;30(9):903-21. [PUBMED: 21190240]
206. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org., 2011.
207. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-4. [PUBMED: 10480822]
208. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005613.pub3]
209. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice//1997 CFR & ICH Guidelines. PA 19063-2043. USA: Barnett International/PAREXEL, 1997.
210. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation 2012.
211. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6):1577-96. [PUBMED: 22526604]
212. Ismail-Beigi F, Craven T, Genuth T, Hramiack I, Karl D. Mixed messages on systemic therapies for diabetic retinopathy? Authors' reply. Lancet 2010; Vol. 376, issue 9751:1462.
213. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54(1):25-31. [PUBMED: 20959956]
214. Jonasson JM, Ljung R, Talbäck M, Haglund B, Udbjörnsdóttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; Vol. 52, issue 9:1745-54.
215. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Annals of Internal Medicine 2009;151(6):394-403. [PUBMED: 19620144]
216. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. The American Journal of Gastroenterology 2009;104(3):546-51. [PUBMED: 19262513]
217. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21(9):1414-31. [PUBMED: 9727886]
218. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [DOI: 10.1136/bmj.c365]
219. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
220. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
221. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. The American Journal of Medicine 2002;113 Suppl 6A:3-11. [PUBMED: 12431757]
222. Liberati A, Altman DG, TetzlaffJ, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: Explanation and elaboration. PLoS Medicine 1999;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
223. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012;Issue 12:Art. No.: MR000033. DOI: 10.1002/14651858.MR000033.pub2.
224. Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutrition, Metabolism, and Cardiovascular Diseases 2009;19(9):596-603. [PUBMED: 19819121]
225. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. Journal of the American College of Cardiology 1995;26(1):57-65. [PUBMED: 7797776]
226. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism, and Cardiovascular Diseases 2009;19(9):604-12. [PUBMED: 19427768]
227. Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes & Vascular Disease Research 2010;7(2):119-30. [PUBMED: 20382775]
228. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
229. Muis MJ, Bots ML, Grobbee DE, Stolk RP. Insulin treatment and cardiovascular disease: friend or foe? A point of view. Diabetic Medicine 2005;22(2):118-26. [PUBMED: 15660727]
230. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
231. Nissen SE, Wolski K. Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine 2010;170(14):1191-201. [PUBMED: 20656674]
232. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice 1995;28(2):103-17. [PUBMED: 7587918]
233. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829-40. [PUBMED: 17765963]
234. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18(6):580-93; discussion 661-6. [PUBMED: 9408720]
235. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998;351(9095):47-52. [PUBMED: 9433436]
236. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373(9677):1765-72. [PUBMED: 19465231]
237. Richter B, Bandeira-Echtler E, BergerhoffK, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006060.pub2]
238. Richter B, Bandeira-Echtler E, BergerhoffK, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006063.pub2]
239. Rind DM. Retinopathy progression in type 2 diabetes. The New England Journal of Medicine 2010; Vol. 363, issue 22:2172-3; author reply 2173-4. [PUBMED: 21105806]
240. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo SM, Roqué i Figuls M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD002966.pub3]
241. Saunders C, Byrne CD, Guthrie B, Lindsay RS, McKnight JA, Philip S, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?. Diabetic Medicine 2013;30(3):300-8. [PUBMED: 23075287]
242. Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82.
243. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
244. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical research ed.) 2010;340:c332. [PUBMED: 20332509]
245. SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009; Vol. 2, issue 1432-0428 (Electronic).
246. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine 2004;141(6):421-31. [PUBMED: 15381515]
247. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. The New England Journal of Medicine 2010;362(9):800-11. [PUBMED: 20200384]
248. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298(10):1189-95. [PUBMED: 17848653]
249. Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. American Journal of Kidney Diseases 2012;60(5):747-69. [PUBMED: 22999165]
250. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2):434-44. [PUBMED: 8432214]
251. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. American Heart Journal 2006;152(1):27-38. [PUBMED: 16824829]
252. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(9):1351-75. [PUBMED: 15116347]
253. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38(1):276-86. [PUBMED: 18824467]
254. Tkac I. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials. Diabetes Research and Clinical Practice 2009;86 Suppl 1:S57-62. [PUBMED: 20115934]
255. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52(11):2288-98. [PUBMED: 19655124]
256. Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PloS One 2013;8(3):e59202. [PUBMED: 23544056]
257. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research edition) 2000;321(7258):405-12. [PUBMED: 10938048]
258. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine 2008;359(15):1577-89. [PUBMED: 18784090]
259. Wang Q, Han P. Intensive glucose control compared with standard therapy in type 2 diabetes: A systematic review. [Chinese]. Chinese Journal of Evidence-Based Medicine 2009;9(7):774-82.
260. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. Journal of Clinical Epidemiology 1998;51(11):903-12. [PUBMED: 9817107]
261. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]
262. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86. [PUBMED: 20042080]
263. Wetterslev J, Engstrøm J, Gluud C, Thorlund K. Trial sequential analysis: methods and software for cumulative meta-analyses. Cochrane Methods. Cochrane Database of Systematic Reviews 2012;Suppl 1 (1-56):29-31.
264. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301(15):1565-72. [PUBMED: 19366776]
265. WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. World Health Organization, 1980.
266. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series 727. World Health Organization, 1985.
267. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998;15(7):539-53. [PUBMED: 9686693]
268. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/index.html. 2011.
269. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5.
270. Wu H, Xu MJ, Zou DJ, Han QJ, Hu X. Intensive glycemic control and macrovascular events in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Chinese Medical Journal 2010;123(20):2908-13. [PUBMED: 21034605]
271. Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. Annals of Medicine 2010;42(4):305-15. [PUBMED: 20429797]
272. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. The New England Journal of Medicine 2010;363(15):1410-8. [PUBMED: 20925543]